New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

被引：0

作者：

Assi, Rita ^{[1
]}

Temraz, Sally ^{[1
]}

Shamseddine, Ali ^{[1
]}

Mukherji, Deborah ^{[1
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, Beirut, Lebanon

来源：

CURRENT DRUG TARGETS | 2016年 / 17卷 / 03期

关键词：

Prostate cancer; androgen receptor; abiraterone; enzalutamide; LIGAND-INDEPENDENT ACTIVATION; CIRCULATING TUMOR-CELLS; ABIRATERONE ACETATE; ENZALUTAMIDE RESISTANCE; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; SPLICE VARIANTS; TYROSINE PHOSPHORYLATION; INCREASED SURVIVAL; AR COREGULATORS;

D O I：

10.2174/1389450116666150907101044

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre- and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.

引用

页码：290 / 302

页数：13

共 50 条

[31] Cell-penetrating bispecific antibodies for targeting androgen receptor signaling in advanced prostate cancer
Goicochea, Nancy L.
Garnovskaya, Maria
Blanton, Mary
Chan, Grace
Weisbart, Richard
Lilly, Michael
CANCER RESEARCH, 2015, 75
[32] Heterogeneity of androgen receptor content in advanced prostate cancer
MagiGalluzzi, C
Xu, XW
Hlatky, L
Hahnfeldt, P
Kaplan, I
Hsiao, PW
Chang, CS
Loda, M
MODERN PATHOLOGY, 1997, 10 (08) : 839 - 845
[33] Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer
Wang, Bin
Lo, U-Ging
Wu, Kaijie
Kapur, Payal
Liu, Xiangyang
Huang, Jun
Chen, Wei
Hernandez, Elizabeth
Santoyo, John
Ma, Shi-Hong
Pong, Rey-Chen
He, Dalin
Cheng, Yi-Qiang
Hsieh, Jer-Tsong
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (10) : 2121 - 2130
[34] Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
Ban, Fuqiang
Leblanc, Eric
Cavga, Ayse Derya
Huang, Chia-Chi Flora
Flory, Mark R.
Zhang, Fan
Chang, Matthew E. K.
Morin, Helene
Lallous, Nada
Singh, Kriti
Gleave, Martin E.
Mohammed, Hisham
Rennie, Paul S.
Lack, Nathan A.
Cherkasov, Artem
CANCERS, 2021, 13 (14)
[35] Novel drugs targeting the androgen receptor pathway in prostate cancer
Joaquin Mateo
Alan Smith
Michael Ong
Johann S. de Bono
Cancer and Metastasis Reviews, 2014, 33 : 567 - 579
[36] Beyond the Androgen Receptor: Targeting Actionable Drivers of Prostate Cancer
Nelson, Peter S.
JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 3
[37] Novel drugs targeting the androgen receptor pathway in prostate cancer
Mateo, Joaquin
Smith, Alan
Ong, Michael
de Bono, Johann S.
CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) : 567 - 579
[38] Context-specific targeting of the androgen receptor in prostate cancer
Abate-Shen, Cory
NATURE GENETICS, 2024, 56 (10) : 2000 - 2001
[39] Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
Bradbury, Robert H.
Hales, Neil J.
Rabow, Alfred A.
Walker, Graeme E.
Acton, David G.
Andrews, David M.
Ballard, Peter
Brooks, Nigel A. N.
Colclough, Nicola
Girdwood, Alan
Hancox, Urs J.
Jones, Owen
Jude, David
Loddick, Sarah A.
Mortlock, Andrew A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (18) : 5442 - 5445
[40] Androgen deprivation is the mainstay of treatment for advanced prostate cancer
Drugs & Therapy Perspectives, 2003, 19 (3) : 16 - 19

← 1 2 3 4 5 →